| 1. |
- Latenstein, Anouk E. J., et al.
(författare)
-
Clinical Outcomes After Total Pancreatectomy A Prospective Multicenter Pan-European Snapshot Study
- 2022
-
Ingår i: Annals of Surgery. - : LIPPINCOTT WILLIAMS & WILKINS. - 0003-4932 .- 1528-1140. ; 276:5, s. E536-E543
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To assess outcomes among patients undergoing total pancreatectomy (TP) including predictors for complications and in-hospital mortality. Background: Current studies on TP mostly originate from high-volume centers and span long time periods and therefore may not reflect daily practice. Methods: This prospective pan-European snapshot study included patients who underwent elective (primary or completion) TP in 43 centers in 16 European countries (June 2018-June 2019). Subgroup analysis included cutoff values for annual volume of pancreatoduodenectomies (<60 vs >= 60). Predictors for major complications and in-hospital mortality were assessed in multivariable logistic regression. Results: In total, 277 patients underwent TP, mostly for malignant disease (73%). Major postoperative complications occurred in 70 patients (25%). Median hospital stay was 12 days (IQR 9-18) and 40 patients were readmitted (15%). In-hospital mortality was 5% and 90-day mortality 8%. In the subgroup analysis, in-hospital mortality was lower in patients operated in centers with >= 60 pancreatoduodenectomies compared <60 (4% vs 10%, P = 0.046). In multivariable analysis, annual volume <60 pancreatoduodenectomies (OR 3.78, 95% CI 1.18-12.16, P = 0.026), age (OR 1.07, 95% CI 1.01-1.14, P = 0.046), and estimated blood loss >= 2L (OR 11.89, 95% CI 2.64-53.61, P = 0.001) were associated with in-hospital mortality. ASA >= 3 (OR 2.87, 95% CI 1.56-5.26, P = 0.001) and estimated blood loss >= 2L (OR 3.52, 95% CI 1.25-9.90, P = 0.017) were associated with major complications. Conclusion: This pan-European prospective snapshot study found a 5% inhospital mortality after TP. The identified predictors for mortality, including low-volume centers, age, and increased blood loss, may be used to improve outcomes.
|
|
| 2. |
|
|
| 3. |
- Proos Vedin, Nathalie, et al.
(författare)
-
Towards A Systematics for the Lowest Excited States of Heteroaromatics Enabled via Cyclic π-Conjugated Carbenes and Heteroelement Analogues
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- The photochemistry of heteroaromatic compounds depends on the character of their lowest electronically excited states, which are of either n,π* or π,π* type. For species with 4n+2 π-electrons, the latter type of states can be antiaromatic to various extents according to Baird’s rule, and thus, highly reactive. The n,π* type of states, on the other hand, will have an odd number of π-electrons leading to an unclear character, spanning from aromatic to antiaromatic. Six-membered ring (6-MR) heteroaromatics with in-plane lone-pair orbitals (nσ, herein n) have either n,π* or π,π* states as their lowest vertically excited states, but regular five-membered ring (5-MR) heteroaromatics with one or two N, O and/or S atoms never have n,π* states as these states. However, this is different for cyclic π-conjugated (potentially aromatic) 5-MR carbenes that have the n orbitals at the divalent C atom. Also 3-MR species have n,π* states as their lowest vertically excited states. Herein, we reveal which factors determine which type of vertical excited state is the lowest in energy for various heteroaromatics. The important factors are (i) the electronegativity of the heteroatom(s), (ii) the valence angle at the heteroatom impacting the lone-pair orbital energy, (iii) the number of π-orbitals and π-electrons, (iv) the degree of (anti)aromatic character of the n,π* state, (v) the electronegativity of atoms adjacent to the heteroatom, and (vi) the spatial extent of the n orbital affecting the intraorbital electron repulsion. Our findings point towards the development of a rational systematics for prediction of which heteroaromatics have n,π* as the first vertical excited states and which ones have π,π* states as these.
|
|
| 4. |
- Reverté, Sara, et al.
(författare)
-
National records of 3000 European bee and hoverfly species : A contribution to pollinator conservation
- 2023
-
Ingår i: Insect Conservation and Diversity. - 1752-458X. ; 16:6, s. 758-775
-
Tidskriftsartikel (refereegranskat)abstract
- Pollinators play a crucial role in ecosystems globally, ensuring the seed production of most flowering plants. They are threatened by global changes and knowledge of their distribution at the national and continental levels is needed to implement efficient conservation actions, but this knowledge is still fragmented and/or difficult to access. As a step forward, we provide an updated list of around 3000 European bee and hoverfly species, reflecting their current distributional status at the national level (in the form of present, absent, regionally extinct, possibly extinct or non-native). This work was attainable by incorporating both published and unpublished data, as well as knowledge from a large set of taxonomists and ecologists in both groups. After providing the first National species lists for bees and hoverflies for many countries, we examine the current distributional patterns of these species and designate the countries with highest levels of species richness. We also show that many species are recorded in a single European country, highlighting the importance of articulating European and national conservation strategies. Finally, we discuss how the data provided here can be combined with future trait and Red List data to implement research that will further advance pollinator conservation.
|
|
| 5. |
- Shah, Rameen, et al.
(författare)
-
ALG13-Congenital Disorder of Glycosylation (ALG13-CDG) : Updated clinical and molecular review and clinical management guidelines
- 2024
-
Ingår i: Molecular Genetics and Metabolism. - 1096-7192. ; 142:2
-
Forskningsöversikt (refereegranskat)abstract
- ALG13-Congenital Disorder of Glycosylation (CDG), is a rare X-linked CDG caused by pathogenic variants in ALG13 (OMIM 300776) that affects the N-linked glycosylation pathway. Affected individuals present with a predominantly neurological manifestation during infancy. Epileptic spasms are a common presenting symptom of ALG13-CDG. Other common phenotypes include developmental delay, seizures, intellectual disability, microcephaly, and hypotonia. Current management of ALG13-CDG is targeted to address patients’ symptoms. To date, less than 100 individuals have been reported with ALG13-CDG. In this article, an international group of experts in CDG reviewed all reported individuals affected with ALG13-CDG and suggested diagnostic and management guidelines for ALG13-CDG. The guidelines are based on the best available data and expert opinion. Neurological symptoms dominate the phenotype of ALG13-CDG where epileptic spasm is confirmed to be the most common presenting symptom of ALG13-CDG in association with hypotonia and developmental delay. We propose that ACTH/prednisolone treatment should be trialed first, followed by vigabatrin, however ketogenic diet has been shown to have promising results in ALG13-CDG. In order to optimize medical management, we also suggest early cardiac, gastrointestinal, skeletal, and behavioral assessments in affected patients.
|
|
